carbamazepine has been researched along with Acute Confusional Senile Dementia in 20 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer's disease, vascular dementia or both." | 9.14 | Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. ( Aga, O; Cvancarova, M; Engedal, K; Olsen, IC; Selbaek, G; Sommer, OH, 2009) |
| "The efficacy, safety, and tolerability of carbamazepine in the treatment of agitation and aggression associated with dementia were assessed." | 9.08 | Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. ( Cox, C; Erb, R; Irvine, C; Jakimovich, L; Patel, S; Podgorski, CA; Tariot, PN, 1998) |
| "BACKGROUND This study was proposed to compare the efficacy and safety of GTM-1, Rapamycin (Rap), and Carbamazepine (CBZ) in managing Alzheimer disease (AD)." | 7.85 | Evaluating the Effectiveness of GTM-1, Rapamycin, and Carbamazepine on Autophagy and Alzheimer Disease. ( Che, H; Fu, P; Gao, Y; Pan, Y; Wang, L; Wang, R; Zhang, L, 2017) |
| "To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer's disease, vascular dementia or both." | 5.14 | Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. ( Aga, O; Cvancarova, M; Engedal, K; Olsen, IC; Selbaek, G; Sommer, OH, 2009) |
| "The efficacy, safety, and tolerability of carbamazepine in the treatment of agitation and aggression associated with dementia were assessed." | 5.08 | Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. ( Cox, C; Erb, R; Irvine, C; Jakimovich, L; Patel, S; Podgorski, CA; Tariot, PN, 1998) |
| "BACKGROUND This study was proposed to compare the efficacy and safety of GTM-1, Rapamycin (Rap), and Carbamazepine (CBZ) in managing Alzheimer disease (AD)." | 3.85 | Evaluating the Effectiveness of GTM-1, Rapamycin, and Carbamazepine on Autophagy and Alzheimer Disease. ( Che, H; Fu, P; Gao, Y; Pan, Y; Wang, L; Wang, R; Zhang, L, 2017) |
| "A 75-year-old white man with Alzheimer disease was observed to have seizures while receiving quetiapine 500 mg/d and carbamazepine 200 mg/d." | 3.72 | Seizures associated with quetiapine treatment. ( Dogu, O; Kaleagasi, HS; Sevim, S, 2003) |
| "Carbamazepine has been reported to decrease agitation associated with various psychiatric disorders and to reduce neuroleptic side effects." | 2.68 | Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. ( Lemke, MR, 1995) |
| "Some comorbidities [e." | 1.48 | A systematic approach for identifying shared mechanisms in epilepsy and its comorbidities. ( Balzer, N; Domingo-Fernández, D; Güldenpfennig, A; Hofmann-Apitius, M; Hoyt, CT, 2018) |
| " Since rapamycin is also an immune suppressor, there is a concern that long-term use of rapamycin may bring severe unwanted side effects." | 1.39 | Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease. ( Le, W; Li, L; Li, T; Liu, H; Tang, Y; Yang, W; Zhang, S; Zhang, X, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.00) | 18.7374 |
| 1990's | 8 (40.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Acunto, CW | 1 |
| Kaplánek, R | 1 |
| Gbelcová, H | 1 |
| Kejík, Z | 1 |
| Bříza, T | 1 |
| Vasina, L | 1 |
| Havlík, M | 1 |
| Ruml, T | 1 |
| Král, V | 1 |
| Boboc, IKS | 1 |
| Cojocaru, A | 1 |
| Nedelea, G | 1 |
| Catalin, B | 1 |
| Bogdan, M | 1 |
| Calina, D | 1 |
| Hoyt, CT | 1 |
| Domingo-Fernández, D | 1 |
| Balzer, N | 1 |
| Güldenpfennig, A | 1 |
| Hofmann-Apitius, M | 1 |
| Zhang, L | 1 |
| Wang, L | 1 |
| Wang, R | 1 |
| Gao, Y | 1 |
| Che, H | 1 |
| Pan, Y | 1 |
| Fu, P | 1 |
| Sommer, OH | 1 |
| Aga, O | 1 |
| Cvancarova, M | 1 |
| Olsen, IC | 1 |
| Selbaek, G | 1 |
| Engedal, K | 1 |
| Xiao, H | 1 |
| Su, Y | 1 |
| Cao, X | 1 |
| Sun, S | 1 |
| Liang, Z | 1 |
| Li, L | 1 |
| Zhang, S | 1 |
| Zhang, X | 1 |
| Li, T | 1 |
| Tang, Y | 1 |
| Liu, H | 1 |
| Yang, W | 1 |
| Le, W | 1 |
| Dogu, O | 1 |
| Sevim, S | 1 |
| Kaleagasi, HS | 1 |
| Lemke, MR | 1 |
| Zayas, EM | 1 |
| Grossberg, GT | 1 |
| Tariot, PN | 1 |
| Erb, R | 1 |
| Podgorski, CA | 1 |
| Cox, C | 1 |
| Patel, S | 1 |
| Jakimovich, L | 1 |
| Irvine, C | 1 |
| Olin, JT | 1 |
| Fox, LS | 1 |
| Pawluczyk, S | 1 |
| Taggart, NA | 1 |
| Schneider, LS | 3 |
| Sobin, PB | 1 |
| Gleason, RP | 1 |
| Murray, GB | 1 |
| Ballinger, BR | 1 |
| Shah, AK | 1 |
| Kurlan, R | 1 |
| Kersun, J | 1 |
| Behr, J | 1 |
| Leibovici, A | 1 |
| Tariot, P | 1 |
| Lichter, D | 1 |
| Shoulson, I | 1 |
| Marin, DB | 1 |
| Greenwald, BS | 1 |
| Risse, SC | 1 |
| Barnes, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) - An Eight Week Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi Center Trial. A Phase III Study[NCT00145691] | Phase 3 | 100 participants | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for carbamazepine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
A meta-analysis of mood stabilizers for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antimanic Agents; Carbamazepine; Female; Humans; Lithium; Male; Middle Aged | 2010 |
Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia.
Topics: Adrenergic beta-Antagonists; Alzheimer Disease; Buspirone; Carbamazepine; Dementia; Humans; Lithium; | 1992 |
Pharmacologic treatment of agitation associated with dementia.
Topics: Affective Symptoms; Aged; Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antipsychotic Agents; | 1986 |
5 trials available for carbamazepine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anticonvulsants; Carbamazepine; Dementia; De | 2009 |
Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamazepine; Drug Therapy, Combination; Female; Follow | 1995 |
Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Carbamazepine; Dementia; Dementia, Vascular; | 1998 |
A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Brief Psychiatric Rating Scale; Carbamazepine; Double | 2001 |
Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Carbamazepine; Cl | 1990 |
12 other studies available for carbamazepine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Metallomics for Alzheimer's disease treatment: Use of new generation of chelators combining metal-cation binding and transport properties.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cations; Cell Proliferation; Cell Survival; Chelating Agen | 2018 |
Chronic Administration of Ion Channel Blockers Impact Microglia Morphology and Function in a Murine Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Carbamazepine; Di | 2023 |
A systematic approach for identifying shared mechanisms in epilepsy and its comorbidities.
Topics: Alzheimer Disease; Carbamazepine; Comorbidity; Data Mining; Databases, Bibliographic; Databases, Gen | 2018 |
Evaluating the Effectiveness of GTM-1, Rapamycin, and Carbamazepine on Autophagy and Alzheimer Disease.
Topics: Alzheimer Disease; Animals; Autophagy; Carbamazepine; Disease Models, Animal; Hippocampus; Male; Maz | 2017 |
Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2013 |
Seizures associated with quetiapine treatment.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Carbamazepine; Dibenzothiazepines; Dose-Response Rela | 2003 |
Treating the agitated Alzheimer patient.
Topics: Adrenergic beta-Antagonists; Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Buspirone; C | 1996 |
Carbamazepine-induced thrombocytopenia.
Topics: Alzheimer Disease; Carbamazepine; Epilepsies, Partial; Humans; Male; Middle Aged; Platelet Count; Th | 1990 |
Carbamazepine in behaviorally disturbed primary dementia patients.
Topics: Aged; Alzheimer Disease; Carbamazepine; Double-Blind Method; Female; Humans; Placebos; Randomized Co | 1990 |
Violence in Alzheimer's disease.
Topics: Aged; Aggression; Alzheimer Disease; Carbamazepine; Electroencephalography; Humans; Violence | 1990 |
Carbamazepine-induced tics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Carbamazepine; Dyskinesia, Drug-Induc | 1989 |
Carbamazepine for aggressive agitation in demented patients during nursing care.
Topics: Aged; Aggression; Alzheimer Disease; Carbamazepine; Female; Humans; Male; Psychomotor Agitation | 1989 |